Science news and discussion on TalkFuse.
Popular heart medication for older patients faces scrutiny as new study evaluates risks
A randomised trial found that stopping statins may bring a small added risk over two years for adults aged 70 and older who take them to prevent a first heart attack or stroke. The results matter because the benefits of continuing cholesterol-lowering treatment in later life are less certain, but the findings do not support a general recommendation to stop.
The study included 1,880 people with at least two chronic conditions and no previous cardiovascular disease. During follow-up, typically about two years and up to four for some, 13% of those assigned to stop statins had a heart attack, an ischaemic stroke or died, compared with 9% of those assigned to continue. There were no meaningful group differences in reported quality of life, muscle pain, falls or muscle loss; treatment changes and limited follow-up mean longer-term effects remain uncertain.
In short
- Stopping statins was linked to more combined serious outcomes.
- 13% of the stop group had an event, versus 9% continuing.
- Researchers say decisions should be made with a healthcare professional.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Continuing statins may be the prudent choice for older adults at elevated risk: in this trial, those assigned to stop had more heart attacks, ischaemic strokes or deaths over follow-up. Even a modest possible benefit can matter when the outcome is serious, particularly for people with several chronic conditions, and the study offers no clear quality-of-life or muscle-related advantage to stopping.
The case against
The case for reviewing or stopping statins is that their preventive benefit in older adults without prior cardiovascular disease is less certain, while treatment adds to the burden of medicines and may not suit every person's priorities or health circumstances. This trial followed participants for a limited period, involved treatment changes and does not settle longer-term effects, so its results need not justify continuing treatment for every individual.